STAR-TREC: evaluating organ preservation in patients with early intermediate rectal cancer

29 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Maria Antonietta Gambacorta, MD, Catholic University of the Sacred Heart, Milan, Italy, comments on the results of the STAR-TREC trial (NCT02945566), a Phase II/III randomized trial on patients with early intermediate rectal cancer. Prof. Gambacorta highlights that the trial found that long-course chemoradiation resulted in a higher rate of organ preservation (80%) compared to short-course radiotherapy (61%) at one year, suggesting that long-course chemoradiation is the preferred treatment for achieving organ preservation in these patients. This interview took place at the ESTRO 2025 congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo